BenzingaAugust 14, 2026 at 6:15 AM NY21 days ago

RBC Capital Initiates Coverage On Krystal Biotech with Outperform Rating, Announces Price Target of $400

RBC Capital analyst Lisa Walter initiates coverage on Krystal Biotech (NASDAQ:KRYS) with a Outperform rating and announces Price Target of $400.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga

Companies in This Story